Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 404


Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.

Falchook AD, Basak R, Mohiuddin JJ, Chen RC.

Cancer. 2016 Aug 1;122(15):2341-9. doi: 10.1002/cncr.30049. Epub 2016 May 18.


The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.


Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 24.


Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.

Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.

Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.


Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer.

Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE.

Ann Oncol. 2012 Sep;23(9):2346-52. doi: 10.1093/annonc/mds001. Epub 2012 Feb 21.


Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.

Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30. doi: 10.1016/j.ijrobp.2009.04.074. Epub 2009 Aug 19.


Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.

Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):64-71. doi: 10.1016/j.ijrobp.2012.11.024. Epub 2013 Feb 22.


Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.

Rose BS, Chen MH, Wu J, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):778-784. doi: 10.1016/j.ijrobp.2016.08.014. Epub 2016 Aug 22.


The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.


The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.

Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, Pollack A.

Cancer. 2013 Mar 1;119(5):1080-8. doi: 10.1002/cncr.27857. Epub 2012 Oct 23.


Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.


The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer.

Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE.

Am J Clin Oncol. 2016 Aug;39(4):368-73. doi: 10.1097/COC.0000000000000071.


Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV.

Cancer. 2015 Aug 15;121(16):2713-9. doi: 10.1002/cncr.29420. Epub 2015 Apr 29.


High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.

Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1473-9. doi: 10.1016/j.ijrobp.2011.10.036. Epub 2012 Jan 13.


Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi: 10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14.


Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52. doi: 10.1016/j.ijrobp.2009.06.038. Epub 2009 Oct 26.


Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.

Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB.

Cancer. 2009 Apr 15;115(8):1784-90. doi: 10.1002/cncr.24176.


Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.

Lin CC, Gray PJ, Jemal A, Efstathiou JA.

J Natl Cancer Inst. 2015 May 9;107(7). pii: djv119. doi: 10.1093/jnci/djv119. Print 2015 Jul.


Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.

Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F, Martinez A.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. doi: 10.1016/j.ijrobp.2010.04.004. Epub 2010 Jun 26.


Supplemental Content

Support Center